𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Inhibition of anti-GD3-ganglioside antibody-induced proliferation of human CD8+ T cells by CD16+ natural killer cells

✍ Scribed by Christine Claus; Jörg Schlaak; Maria Dittmayer; Karl-Hermann Meyer Zum; Büschenfelde; Wolfgang Dippold

Publisher
John Wiley and Sons
Year
1994
Tongue
English
Weight
572 KB
Volume
24
Category
Article
ISSN
0014-2980

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Induction of tumor-cell lysis by bi-spec
Induction of tumor-cell lysis by bi-specific antibody recognizing ganglioside GD2 and T-cell antigen CD3
✍ Helga Bernhard; Julia Karbach; Karl-Hermann Meyer Zum Büschenfelde; Wolfgang Str 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 French ⚖ 589 KB

## Abstract Human tumor cells expressing ganglioside GD2 were lysed by various effector populations targeted with an anti‐CD3‐anti‐GD2 bi‐specific antibody (BAb CD3 x GD2). This antibodyheteroconjugate was prepared by chemically cross‐linking the OKT‐3 monoclonal antibody (MAb) reactive with CD3 an

A CD16/CD30 bispecific monoclonal antibo
A CD16/CD30 bispecific monoclonal antibody induces lysis of hodgkin's cells by unstimulated natural killer cells In AND In vivo
✍ Andreas Hombach; Wolfram Jung; Christoph Pohl; Christoph Renner; Ugur Sahin; Rud 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 French ⚖ 808 KB

In order to target NK cells against the Hodgkin's-derived cell line L540, we developed bispecific monoclonal antibodies (Bi-MAbs) by somatic hybridization of the 2 mouse hybridoma cell lines HRS-3 and A9 which produce monoclonal antibodies (MAbs) with reactivity against the Hodgkin and Reed-Sternber

NKG2A is a marker for acquisition of reg
NKG2A is a marker for acquisition of regulatory function by human CD8+ T cells activated with anti-CD3 antibody
✍ Vitaly Ablamunits; Octavian Henegariu; Paula Preston-Hurlburt; Kevan C. Herold 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 435 KB 👁 1 views

## Abstract Treatment with anti‐CD3 mAb modulates immune responses that cause type 1 diabetes and other diseases. CD8^+^ Tregs can be induced in vitro and in vivo by mAb. However, 1/3 of patients do not respond to drug therapy and in an equal proportion, anti‐CD3 mAb does not induce Tregs in vitro.